Publications

1. Montenegro M, Cutrer FM. Cough, Exertional, and Sex Headaches. Neurol Clin. 2024 May; 42 (2):599-614 Epub 2024 Jan 09
   View PubMed
2. Chen YC, Wang H, Mandrekar JN, Robertson CE, Starling AJ, Cutrer FM, Chiang CC. Pharmacogenomic study-A pilot study of the effect of pharmacogenomic phenotypes on the adequate dosing of verapamil for migraine prevention. Pharmacogenomics J. 2024 Apr 9; 24 (3):11 Epub 2024 Apr 09
   View PubMed
3. Sanchez Del Rio M, Cutrer FM. Pathophysiology of migraine aura. Handb Clin Neurol. 2023; 198:71-83
   View PubMed
4. Chiang CC, Chhabra N, Chao CJ, Wang H, Zhang N, Lim E, Baez-Suarez A, Attia ZI, Schwedt TJ, Dodick DW, Cutrer FM, Friedman PA, Noseworthy PA. Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men. Headache. 2022 Sep; 62 (8):939-951 Epub 2022 June 08
   View PubMed
5. Zandieh A, Cutrer FM. OnabotulinumtoxinA in chronic migraine: is the response dose dependent? BMC Neurol. 2022 Jun 13; 22 (1):218 Epub 2022 June 13
   View PubMed
6. Schwedt TJ, Sahai-Srivastava S, Murinova N, Birlea M, Ahmed Z, Digre K, Lopez K, Mullally W, Blaya MT, Pippitt K, Cutrer FM, DeLange J, Schecht H, Rizzoli P, Lane J, Wald J, Cortez MM, Martin VT, Spare NM, Hentz JG, Robert T, Dodick DW, MOTS Investigators. Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial. Cephalalgia. 2021 Sep; 41 (10):1053-1064 Epub 2021 May 02
   View PubMed
7. Cutrer FM, Moyer AM, Atkinson EJ, Wang L, Tian S, Wu Y, Garza I, Robertson CE, Huebert CA, Moore BE, Klein CJ. Genetic variants related to successful migraine prophylaxis with verapamil. Mol Genet Genomic Med. 2021 Jun; 9 (6):e1680 Epub 2021 Apr 07
   View PubMed
8. Foroozan R, Cutrer FM. Transient Neurologic Dysfunction in Migraine. Neurol Clin. 2019 Nov; 37 (4):673-694 Epub 2019 Aug 28
   View PubMed
9. Kok SN, Hayes SN, Cutrer FM, Raphael CE, Gulati R, Best PJM, Tweet MS. Prevalence and Clinical Factors of Migraine in Patients With Spontaneous Coronary Artery Dissection. J Am Heart Assoc. 2018 Dec 18; 7(24):e010140.
   View PubMed
10. Whealy M, Nanda S, Vincent A, Mandrekar J, Cutrer FM. Fibromyalgia in migraine: a retrospective cohort study. J Headache Pain. 2018 Jul 31; 19 (1):61 Epub 2018 July 31
    View PubMed
11. Singh TD, Cutrer FM, Smith JH. Episodic status migrainosus: A novel migraine subtype. Cephalalgia. 2018 Feb; 38 (2):304-311 Epub 2017 Jan 05
    View PubMed
12. Kissoon NR, Cutrer FM. Aura and Other Neurologic Dysfunction in or with Migraine. Headache. 2017 Jul; 57 (7):1179-1194 Epub 2017 May 19
    View PubMed
13. Martinez-Thompson JM, Garza I, Cutrer FM, Robertson CE. C1 Myelitis Presenting With Neuralgic Otalgia. Headache. 2017 Jan; 57 (1):126-127 Epub 2016 Nov 11
    View PubMed
14. Hubbard CS, Becerra L, Smith JH, DeLange JM, Smith RM, Black DF, Welker KM, Burstein R, Cutrer FM, Borsook D. Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal. Front Hum Neurosci. 2016; 10:497 Epub 2016 Oct 06
    View PubMed
15. Mathew PG, Cutrer FM, Garza I. A touchy subject: an assessment of cutaneous allodynia in a chronic migraine population. J Pain Res. 2016; 9:101-4 Epub 2016 Feb 24
    View PubMed
16. Kumar R, Jacob JT, Welker KM, Cutrer FM, Link MJ, Atkinson JL, Wetjen NM. Superficial siderosis of the central nervous system associated with incomplete dural closure following posterior fossa surgery: report of 3 cases. J Neurosurg. 2015 Nov; 123: (5)1326-30.
    View PubMed
17. DeLange JM, Cutrer FM. Our evolving understanding of migraine with aura. Curr Pain Headache Rep. 2014 Oct; 18 (10):453
    View PubMed
18. Mathew PG, Cutrer FM. Injecting under pressure: the pain of low csf pressure headache responsive to botulinum toxin injections. Curr Neurol Neurosci Rep. 2014 Sep; 14(9):477.
    View PubMed
19. Cutrer FM, DeLange J. Cough, exercise, and sex headaches. Neurol Clin. 2014 May; 32(2):433-50. Epub 2014 Feb 28.
    View PubMed
20. Cutrer F, Sullivan, Atkinson EJ. Hormonally modulated migraine is associated with single nucleotide polymorphisms within genes involved in dopamine metabolism. Open Journal of Genetics.2013;Vol.3 :
    
21. Smith JH, Robertson CE, Garza I, Cutrer FM. Triggerless neuralgic otalgia: a case series and systematic literature review. Cephalalgia. 2013 Aug; 33 (11):914-23 Epub 2013 Feb 26
    View PubMed
22. Moon JS, Smith JH, Lahr BD, Cutrer FM. Longitudinal associations of migraine and depressive symptoms: a cohort analysis. Psychosomatics. 2013 Jul-Aug; 54 (4):317-27 Epub 2012 Dec 27
    View PubMed
23. Cutrer FM, Smith JH. Human studies in the pathophysiology of migraine: genetics and functional neuroimaging. Headache. 2013 Feb; 53 (2):401-12 Epub 2012 Dec 20
    View PubMed
24. Cutrer FM, Smith JH. 15th International Headache Congress: basic science highlights. Headache. 2012 May; 52(5):851-8. Epub 2012 Apr 05.
    View PubMed
25. Smith JH, Butterfield JH, Cutrer FM. Primary headache syndromes in systemic mastocytosis. Cephalalgia. 2011 Nov; 31(15):1522-31. Epub 2011 Sep 29.
    View PubMed
26. Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55.
    View PubMed
27. Smith JH, Butterfield JH, Pardanani A, DeLuca GC, Cutrer FM. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg. 2011 Sep; 113(7):570-4. Epub 2011 Jun 12.
    View PubMed
28. Smith JH, Cutrer FM. Numbness matters: a clinical review of trigeminal neuropathy. Cephalalgia. 2011 Jul; 31(10):1131-44. Epub 2011 May 31.
    View PubMed
29. Rollene NL, Khan Z, Schroeder DR, Cutrer FM, Coddington CC. Migraines and ovarian hyperstimulation syndrome: a dopamine connection. Fertil Steril. 2011 Jan; 95(1):417-9.
    View PubMed
30. Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia. 2010 Aug; 30 (8):1000-6
    View PubMed
31. Bartleson JD, Cutrer FM. Migraine update. Diagnosis and treatment. Minn Med. 2010 May; 93(5):36-41.
    View PubMed
32. Garza I, Cutrer FM. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A. Cephalalgia. 2010 Apr; 30(4):500-3. Epub 2010 Feb 01.
    View PubMed
33. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2010 Apr; 30 (2):120-30 Epub 2010 Mar 29
    View PubMed
34. Cutrer FM, Martin VT. Migraine clinical diagnostic criteria. Handb Clin Neurol. 2010; 97:295-302
    View PubMed
35. McKenzie JA, Cutrer FM. How well do headache patients remember? A comparison of self-report measures of headache frequency and severity in patients with migraine. Headache. 2009 May; 49(5):669-72.
    View PubMed
36. Foroozan R, Cutrer FM. Transient neurologic dysfunction in migraine. Neurol Clin. 2009 May; 27(2):361-78.
    View PubMed
37. Cutrer FM, Charles A. The neurogenic basis of migraine. Headache. 2008 Oct; 48(9):1411-4.
    View PubMed
38. Cutrer FM. Functional imaging in primary headache disorders. Headache. 2008 May; 48: (5)704-6.
    View PubMed
39. Cutrer FM, Huerter K. Migraine aura. Neurologist. 2007 May; 13(3):118-25.
    View PubMed
40. Cutrer FM, Black DF. Imaging findings of migraine. Headache. 2006 Jul-Aug; 46(7):1095-107.
    View PubMed
41. Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia. 2006 Jun; 26 (6):747-51
    View PubMed
42. Fattah QA, Cutrer FM. Cluster headache with short-lived visual symptoms. Cephalalgia. 2006 Apr; 26(4):492-3.
    View PubMed
43. Cutrer FM. Pathophysiology of migraine. Semin Neurol. 2006 Apr; 26(2):171-80.
    View PubMed
44. Ferrari MD, Goadsby PJ, Lipton RB, Dodick DW, Cutrer FM, McCrory D, Williams P. The use of multiattribute decision models in evaluating triptan treatment options in migraine. J Neurol. 2005 Sep; 252(9):1026-32. Epub 2005 Mar 11.
    View PubMed
45. Black DF, Swanson JW, Eross E, Cutrer FM. Secondary SUNCT due to intraorbital, metastatic bronchial carcinoid. Cephalalgia. 2005 Aug; 25 (8):633-5
    View PubMed
46. Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW, McCrory D, Liberman JN, Williams P. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin 2005 Mar; 21(3):413-24.
    View PubMed
47. Dodick DW, Lipton RB, Ferrari MD, Goadsby PJ, McCrory D, Cutrer FM, Williams P. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr Pain Headache Rep. 2004 Dec; 8 (6):435-42
    View PubMed
48. Cutrer FM, Goadsby PJ, Ferrari MD, Lipton RB, Dodick DW, McCrory D, Williams P. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin Ther. 2004 Sep; 26(9):1533-45.
    View PubMed
49. Cutrer FM, Boes CJ. Cough, exertional, and sex headaches. Neurol Clin. 2004 Feb; 22(1):133-49.
    View PubMed
50. Welch KM, Cutrer FM, Goadsby PJ. Migraine pathogenesis - Neural and vascular mechanisms. Neurology. 2003 Apr 8; 60(7 Suppl 2):S9-S14.
    View PubMed
51. Jamieson D, Cutrer FM, Goldstein J, Dayno J, Hu XH. Real-world experiences in migraine therapy with rizatriptan. Headache. 2003 Mar; 43(3):223-30.
    View PubMed
52. Dodick DW, Lipton RB, Goadsby PJ, McCrory D, Ferrari MD, Williams P, Cutrer FM. Prioritizing triptan treatment attributes: a pilot study. Neurology. 2002; 58(Suppl 3):A129.
    
53. Hadjikhani N, Sanchez del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KW, F, Cutrer FM, Rosen BR, Tootell RBH, Sorensen GA, Moskowitz MA. Mechanisms of Migraine Aura Revealed by fMRI in: Human Visual Cortex Proc. Nat Acad Sci. 2001; 98(8):4687-92.
    
54. Burstein R, Cutrer FM, Yarnitsky D. The Development of Cutaneous Allodynia During A Migraine Attack. Brain. 2000; 123(Pt 8):1703-9.
    View PubMed
55. Cutrer FM, Yu X, Ayata G, Waeber C, Moskowitz MA. Effects of U-109,291a Selective h5-HT1D Agoniston Induced Dural Plasma Extravasation and c-Fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology. 1999; 38(7):1043-53.
    View PubMed
56. Cutrer FM, Mitsikostas D, Ayata G, Moskowitz MA. Attenuation by butalbital of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Headache. 1999; 39:697-704.
    View PubMed
57. Mitsikostas D, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol. 1999; 127(3):623-30.
    View PubMed
58. Sanchez del Rio M, Bakker D, Wu O, Agosti R, Mitsikostatas D, Ostergaard L, Wells WA, Rosen BR, Sorensen G, Moskowitz MA, Cutrer FM. Perfusion Weighted Imaging During Migraine: Spontaneous Visual Aura and Headache. Cephalagia. 1999; 19:701-7.
    
59. Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain. 1998 May; 76 (1-2):239-48
    View PubMed
60. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez del Rio M, Lee EJ, Rosen BR, Moskowitz MA. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol. 1998 Jan; 43(1):25-31.
    View PubMed
61. Yu X, Cutrer FM, Moskowitz MA, Waeber C. The 5-HT1D receptor antagonist GR-127,935 reverses inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacol. 1997; 36:83-91.
    
62. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 1996; 36:579-85.
    View PubMed
63. Cutrer FM, Moussaoui S, Garret C, Moskowitz MA. The Non-Peptide NK1 antagonist RPR 100893 decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience 64;. 1995; 3: 741-50.
    
64. Cutrer FM, Schoenfeld D, Limmroth V, Panahian N, Moskowitz MA. Suppression by the sumatriptan analogueCP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 114 987-992. 1995; 0: 0.
    
65. Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Moskowitz MA. Peripheral GABAA receptor mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116 1661-1667. 1995; 0: 0.
    
66. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. The suppression of c-fos expression in the trigeminal nucleus caudalis by valproate. Br J Pharmacol 116 3199-324. 1995; 0: 0.
    
67. Cutrer F, Baloh , R. Migraine Associated Dizziness Headache.1992;32:(8)300-304.
    
68. Gaitan E, Cooksey R, Cutrer FM, et al. C-Glycosylflavones: Goitrogens in Millet. Frontiers of Thyroidology. 1987; 2:971-5.